Medicare Advantage Denies 17 Percent of Initial Claims; Most Denials Are Reversed

A Health Affairs study analyzing Medicare Advantage claims data covering approximately 30 percent of the MA market reveals a striking pattern: MA plans deny 17 percent of initial claims, but 57 percent of those denials are ultimately overturned through appeals or resubmission. The net effect is a 7 percent reduction in provider revenue — money that was earned through legitimate clinical services but required significant administrative effort to collect. For physician practices serving MA beneficiaries, these findings quantify both the scope of the denial problem and the return on investment of systematic appeal processes.

The 17 Percent Initial Denial Rate

A 17 percent initial denial rate means that roughly one in six claims submitted to Medicare Advantage plans is initially rejected. This is not a marginal inefficiency. For a practice submitting 500 MA claims per month, 85 claims will be denied on first submission. Each denial represents administrative work: identifying the denial, interpreting the reason code, deciding whether to appeal, gathering supporting documentation, and submitting the appeal within the payer's timeline.

The 17 percent figure is also a composite. Some service categories experience significantly higher denial rates than others. Advanced imaging, specialty drugs, surgical procedures, and rehabilitation services tend to trigger denial rates well above the average, while routine office visits and standard laboratory tests are denied less frequently. Practices heavily concentrated in high-denial service categories face an even steeper administrative burden than the overall figure suggests.

The 57 Percent Overturn Rate

The finding that 57 percent of denials are ultimately overturned is the most operationally significant data point in the study. It means that the majority of initial denials do not reflect legitimate coverage or medical necessity concerns — they represent a first-pass rejection that, when challenged with evidence, is reversed. This overturn rate has direct implications for practice strategy:

• Practices that do not appeal MA denials are accepting revenue loss on claims where they would more likely than not prevail
• The economic return on appealing MA denials is positive in the aggregate, even accounting for the staff time required
• A 57 percent overturn rate suggests systemic over-denial by MA plans rather than targeted clinical review
• The remaining 43 percent of denials that are upheld may include cases where documentation was genuinely insufficient, creating an opportunity for upstream improvement

The Revenue Impact

The study's finding of a net 7 percent revenue reduction after appeals is important context. Even with a 57 percent overturn rate, the denial-and-appeal cycle still costs providers real money. The 7 percent net loss reflects both the denials that are never appealed and those where appeals are unsuccessful. It does not include the administrative cost of managing the appeal process itself — staff salaries, technology costs, and the opportunity cost of time spent on denials rather than patient care.

For a practice generating $5 million annually from MA patients, a 7 percent net revenue reduction represents $350,000 in lost revenue. A portion of that loss is recoverable through more systematic appeal processes. A portion reflects denials that could be prevented through better documentation, coding, or pre-submission review. The study does not disaggregate these components, but it establishes the total economic opportunity.

What This Means for Practice Strategy

The Health Affairs data makes the business case for systematic MA denial management unambiguous. With initial denial rates at 17 percent and overturn rates at 57 percent, the expected value of appealing MA denials is positive. Practices without a structured appeal process for MA claims are leaving measurable revenue on the table. The question is not whether to appeal — it is how to appeal efficiently enough that the cost of the appeal process does not consume the recovered revenue. That efficiency requires structured workflows, evidence-based appeal templates, and tracking systems that prioritize high-value denials. The data says the revenue is recoverable. The operational question is whether your practice has the infrastructure to recover it.